In HER2+ breast tumors, despite a higher degree of inherent immunogenicity, resistance further depends on HER2-driven signaling that activates pro-tumor pathways, such as PI3K/AKT, and by adaptive mechanisms, including HER2 downregulation or shedding [308]. This evidence concerns the gene ERBB2 and breast neoplasm.